Deliver Your News to the World

GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries


London, UK - GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to WHO for distribution to developing countries most in need. GSK is working with WHO and health authorities to prepare for initial shipments of the vaccine to developing countries by the end of November.

“GSK is committed to supporting governments and health authorities around the world in their efforts to protect their populations against this pandemic. Our commitment recognises the needs of developing countries, and this donation of 50 million doses will enable vaccination to begin soon in some of the world’s poorest countries.” said Andrew Witty, CEO, GlaxoSmithKline.

“We welcome this very generous donation by GlaxoSmithKline, which will go to protect the health of the world’s poorest people. This is a real gesture of global solidarity towards those who would not be otherwise able to have access to the vaccine,” said Dr. Margaret Chan, Director–General, WHO. “WHO will now work to see that these vaccines are distributed to those who need them.”

In addition to this agreement on vaccines, GSK continues to have discussions with WHO about a donation of its antiviral medicine, Relenza. A tiered-pricing policy based on World Bank classification of countries is also in effect for this antiviral medicine, and the company is making Relenza Rotacaps and Diskhaler available at not-for-profit prices to the world’s 50 least developed countries.

GSK is committed to facilitating equitable access to all these interventions to all countries. The company strongly endorses the principles set out by the Gates Foundation to help guide global allocation of pandemic vaccines and reiterates that the global community should take all steps necessary to protect all populations, including those without resources to protect themselves.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under ’Risk Factors’ in the ’Business Review’ in the company’ s Annual Report on Form 20-F for 2008.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.